Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTP0206EA
- Development stage
- Preclinical
- Lead developer
- Trinity College Dublin
01
Overview
NTP0206EA is a novel plant extract derived from Irish bogland species, identified through the "Unlocking Nature’s Pharmacy from Bogland Species" project. Developed by researchers at Trinity College Dublin and St. James's Hospital, the extract was selected for its immunomodulatory potential based on traditional medicine and in vitro screening. In ex vivo colonic tissue explant models, NTP0206EA has been shown to significantly reduce the secretion of Interleukin-10 (IL-10) in patients with ulcerative colitis. It is currently being explored as a potential therapeutic candidate for the treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
02
Targets
IL10 (Interleukin-10)
Beyond the preview
Go deeper on NTP0206EA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTP0206EA.